Last updated: February 3, 2026
erview:
Acthar Gel (repository Corticotropin) is a long-standing pharmaceutical product used for various medical conditions, notably multiple sclerosis relapses and infantile spasms. It is marketed by Mallinckrodt Pharmaceuticals, which has maintained exclusive rights for decades. Its patent and intellectual property status influence its market and investment landscape.
Market Position and Revenue:
In 2022, Acthar generated approximately $270 million, a decline from peak revenues exceeding $400 million in earlier years due to patent expiry and biosimilar threat. The drug's sales are principally driven by rare and serious indications, such as infantile spasms, with off-label use in other autoimmune conditions. Sales are sensitive to insurance reimbursement policies given its high cost, typically exceeding $30,000 per course of treatment.
Patent and Legal Landscape:
The original patents expired or are nearing expiration. Mallinckrodt engaged in litigation to defend certain formulations and methods of use, but patent protections are diminishing. As patent exclusivity erodes, biosimilar entries could challenge Acthar’s market share, though current barriers remain substantial due to formulation complexity and regulatory hurdles.
Regulatory and Patent Exclusivity:
Acthar’s approval was granted in 1952, with multiple patent filings to extend exclusivity. The most recent patent was invalidated or expired in the US by 2019. Regulatory exclusivity for new formulations or methods could be granted under FDA pathways like orphan or new chemical entity designations, though these are limited for Acthar.
Pipeline and Clinical Development:
No direct pipeline products aim to substitute for Acthar; efforts focus on alternative treatments for its key indications. Ongoing clinical trials for multiple sclerosis or infantile spasms are limited; most research targets new therapeutics rather than reformulations or biosimilars.
Financial Analysis and Investment Risks:
- Revenue decline risks from biosimilar entry and patent loss.
- High manufacturing costs due to complex extraction from porcine tissue.
- Heavy reliance on U.S. reimbursement policies.
- Limited pipeline activity reduces long-term growth prospects.
- Litigation and legal challenges to patent and exclusivity weaken financial stability.
Strategic Considerations:
Investors should monitor legal developments, patent statuses, and regulatory changes impacting biosimilar pathways. Competitor entrants or new formulations could significantly erode market share. The company's restructuring efforts and diversification may shape future stability.
Key Factors for Evaluation:
- Patent expiration timeline (post-2019).
- Biosimilar filings and approvals.
- Reimbursement landscape dynamics.
- Development or acquisition of alternative therapies.
- Company financial health, including debt levels and litigation costs.
Summary:
Acthar is a legacy product with declining revenue due to patent expiry and biosimilar competition. Its market hinges on unique formulation challenges and regulatory protections, which are waning. Investment relies heavily on legal protections and the stability of current market access. Long-term growth prospects diminish absent new formulations or indications.
Key Takeaways
- Revenue peaked over $400 million historically; now around $270 million.
- Patent expiry or invalidation occurred after 2019, exposing the product to biosimilar competition.
- The product's manufacturing complexity and regulatory protections limit biosimilar entry.
- Future revenues depend on legal and regulatory developments and reimbursement policies.
- No clear pipeline options present near-term revenue growth.
FAQ
1. When did Acthar’s key patents expire?
Most patents expired or were invalidated after 2019, opening the market to biosimilar competition.
2. How vulnerable is Acthar to biosimilar competition?
High barriers exist due to formulation complexity and regulatory requirements, delaying biosimilar entry, but eventual competition is likely once patent protections fade.
3. What are the primary indications for Acthar?
Infantile spasms, multiple sclerosis relapses, and certain autoimmune conditions.
4. How does reimbursement impact Acthar’s sales?
High treatment costs make insurance coverage critical; reimbursement policies can significantly influence sales volume.
5. Are there pathways to extend Acthar’s market exclusivity?
Limited; FDA pathways for exclusivity primarily include orphan drug designation, but these are not broadly applicable for Acthar’s status.
References
[1] Mallinckrodt’s 2022 financial filings.
[2] FDA approval history.
[3] Market research reports on Acthar sales and biosimilar developments.
